Search
for
Sort by
Research
360-390 / 1000+ results
research S87 Image guided radiotherapy (IGRT) in stage III prostate cancer: analysis of acute toxicity
IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
research Contrast-Enhanced Ultrasound (CEUS) Evaluation of Canine Prostatic Hyperplasia before and after Osaterone Acetate Therapy: Preliminary Results
Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.
research A Case of Proliferating Trichilemmal Cyst with Trichoepitheliomatous Change
A young woman had a rare scalp tumor usually found in older women.
research A Prospective, 1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category III Prostatitis/Chronic Pelvic Pain Syndrome
Finasteride improves chronic pelvic pain, saw palmetto doesn't.
research Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
research Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride
Dutasteride does not impair mental function in elderly men with enlarged prostate.
research Medical management of benign prostatic hyperplasia
Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
research Effectiveness and safety of finasteride in male chronic pelvic pain syndrome
Finasteride effectively reduces symptoms of male chronic pelvic pain syndrome with few side effects.
research S1 OPIOID RECEPTOR AGONISTS AND SERUM PROSTATE SPECIFIC ANTIGENE LEVEL: IS THERE A ROLE FOR PROSTATE CANCER CONTROL AND CHEMOPREVENTION?
Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research MP85-04 DOES IMIPRAMINE AND PSEUDOEPHEDRINE MEDICAL TREATMENT HAVE CLINICAL IMPLICATION IN TREATMENT OF RETROGRADE EJACULATION CAUSED BY DIABETES MELLITUS?
Imipramine and pseudoephedrine treatment can effectively restore normal ejaculation in patients with diabetes, increasing their chances for pregnancy.
research Tamsulosin versus finasteride: effect on bother and urinary flow
Tamsulosin works faster, but both drugs have similar effects after 6 months.
research MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
research Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer
Prostate cancer was a major health issue in 2009, especially for Black men, and targeting the 5alpha-reductase enzyme could help in its prevention and treatment.
research Інгібітор 5α-редуктази дутастерид при лікуванні доброякісної гіперплазії передміхурової залози: системний огляд та мета-аналіз
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
research Long-Term Effectiveness of Finasteride for BPH
Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.
research PREVALENCIA DE APEGO AL TRATAMIENTO CON FINASTERIDA EN PACIENTES CON HIPERPLASIA BENIGNA DE PRÓSTATA DE UN SERVICIO DE UROLOGÍA DEL I.S.S.S.T.E.
Adherence to finasteride treatment for prostate issues is generally low.
research 5α‐Reductase Inhibitors
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
research Testosterone replacement in the setting of Finasteride therapy: a therapeutic dilemma
research 혈정액증에서의 Finasteride 효과
Finasteride is more effective for treating hemospermia related to prostatitis.
research Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats
Ganoderma lucidum may help treat enlarged prostate in rats.
research Гормональный дисбаланс как фактор развития хронического простатита: механизмы и перспективы терапии
Hormonal imbalance contributes to chronic prostatitis and affects male reproductive health.
research Evaluation of intralesional injection of platelet derived growth factors PDGF ma in patients with Peyronie's disease
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
research Kombinationsbehandlung des BPS mit Tamsulosin und Finasterid
research EFFECT OF A COMBINATION OF DUTASTERIDE AND PARENTERAL TESTOSTERONE UNDECANOATE ON TESTOSTERONE DEFICIENCY SYMPTOMS AND PROSTATE IN PATIENTS WITH TESTOSTERONE DEFICIENCY AND BENIGN PROSTATIC HYPERPLASIA
The combination treatment reduced prostate size and improved testosterone deficiency symptoms but was less effective for sexual function.
research Hydroxychloroquine modulates the progression of experimentally induced benign prostatic hyperplasia in rats via targeting EGFR/ERK/STAT3 and AR/FOXO1/TRAIL pathways: computational and in vivo studies
Hydroxychloroquine may help treat benign prostatic hyperplasia by reducing inflammation and promoting cell death.
research The BJUI 's clinical trials initiative
The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
research Clinical and metabolic implications of obesity in prostate cancer: is testosterone a missing link?
Higher BMI and lower testosterone are linked to more aggressive prostate cancer.